{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:27:15Z","timestamp":1790346435993,"version":"4.1.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100006955","name":"U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health","doi-asserted-by":"publisher","award":["UG3AI150552"],"award-info":[{"award-number":["UG3AI150552"]}],"id":[{"id":"10.13039\/100006955","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006955","name":"U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health","doi-asserted-by":"publisher","award":["UG3AI150552"],"award-info":[{"award-number":["UG3AI150552"]}],"id":[{"id":"10.13039\/100006955","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006955","name":"U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health","doi-asserted-by":"publisher","award":["L40AI140341"],"award-info":[{"award-number":["L40AI140341"]}],"id":[{"id":"10.13039\/100006955","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006955","name":"U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health","doi-asserted-by":"publisher","award":["K08AI153767"],"award-info":[{"award-number":["K08AI153767"]}],"id":[{"id":"10.13039\/100006955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Protoc"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1038\/s41596-025-01154-8","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T04:01:51Z","timestamp":1740974511000},"page":"2735-2770","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Peptide-enabled ribonucleoprotein delivery for CRISPR engineering (PERC) in primary human immune cells and hematopoietic stem cells"],"prefix":"10.1038","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4950-1557","authenticated-orcid":false,"given":"Srishti U.","family":"Sahu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madalena","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3784-3565","authenticated-orcid":false,"given":"Joseph J.","family":"Muldoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunica","family":"Asija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8937-8397","authenticated-orcid":false,"given":"Stacia K.","family":"Wyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Netravathi","family":"Krishnappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"de O\u00f1ate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8262-1190","authenticated-orcid":false,"given":"Justin","family":"Eyquem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6808-2717","authenticated-orcid":false,"given":"David N.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0644-5540","authenticated-orcid":false,"given":"Ross C.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"key":"1154_CR1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jconrel.2022.01.013","volume":"342","author":"EA Taha","year":"2022","unstructured":"Taha, E. A., Lee, J. & Hotta, A. Delivery of CRISPR-Cas tools for in vivo genome editing therapy: trends and challenges. J. Control. Release 342, 345\u2013361 (2022).","journal-title":"J. Control. Release"},{"key":"1154_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/d41587-023-00016-6","volume":"42","author":"C Sheridan","year":"2023","unstructured":"Sheridan, C. The world\u2019s first CRISPR therapy is approved: who will receive it? Nat. Biotechnol. 42, 3\u20134 (2023).","journal-title":"Nat. Biotechnol."},{"key":"1154_CR3","doi-asserted-by":"publisher","first-page":"eaba7365","DOI":"10.1126\/science.aba7365","volume":"367","author":"EA Stadtmauer","year":"2020","unstructured":"Stadtmauer, E. A. et al. CRISPR-engineered T cells in patients with refractory cancer. Science 367, eaba7365 (2020).","journal-title":"Science"},{"key":"1154_CR4","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa2300709","volume":"389","author":"R Chiesa","year":"2023","unstructured":"Chiesa, R. et al. Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia. N. Engl. J. Med. 389, 899\u2013910 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1154_CR5","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.3390\/cells12081103","volume":"12","author":"N Bhokisham","year":"2023","unstructured":"Bhokisham, N. et al. CRISPR-Cas system: the current and emerging translational landscape. Cells 12, 1103 (2023).","journal-title":"Cells"},{"key":"1154_CR6","doi-asserted-by":"publisher","first-page":"1111777","DOI":"10.3389\/fimmu.2023.1111777","volume":"14","author":"X Liu","year":"2023","unstructured":"Liu, X. et al. Advances in CRISPR\/Cas gene therapy for inborn errors of immunity. Front. Immunol. 14, 1111777 (2023).","journal-title":"Front. Immunol."},{"key":"1154_CR7","doi-asserted-by":"publisher","first-page":"1292452","DOI":"10.3389\/fmed.2023.1292452","volume":"10","author":"S Zhang","year":"2023","unstructured":"Zhang, S. et al. Current trends of clinical trials involving CRISPR\/Cas systems. Front. Med. 10, 1292452 (2023).","journal-title":"Front. Med."},{"key":"1154_CR8","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1016\/j.cell.2018.10.024","volume":"175","author":"E Shifrut","year":"2018","unstructured":"Shifrut, E. et al. Genome-wide CRISPR screens in primary human T cells reveal key regulators of immune function. Cell 175, 1958\u20131971.e15 (2018).","journal-title":"Cell"},{"key":"1154_CR9","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/s41586-023-06835-6","volume":"625","author":"R Schmidt","year":"2024","unstructured":"Schmidt, R. et al. Base-editing mutagenesis maps alleles to tune human T cell functions. Nature 625, 805\u2013812 (2024).","journal-title":"Nature"},{"key":"1154_CR10","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.stem.2017.07.015","volume":"21","author":"Z Tothova","year":"2017","unstructured":"Tothova, Z. et al. Multiplex CRISPR\/Cas9-based genome editing in human hematopoietic stem cells models clonal hematopoiesis and myeloid neoplasia. Cell Stem Cell 21, 547\u2013555.e8 (2017).","journal-title":"Cell Stem Cell"},{"key":"1154_CR11","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/nature15521","volume":"527","author":"MC Canver","year":"2015","unstructured":"Canver, M. C. et al. BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. Nature 527, 192\u2013197 (2015).","journal-title":"Nature"},{"key":"1154_CR12","doi-asserted-by":"publisher","first-page":"e65421","DOI":"10.7554\/eLife.65421","volume":"11","author":"NS Ravi","year":"2022","unstructured":"Ravi, N. S. et al. Identification of novel HPFH-like mutations by CRISPR base editing that elevate the expression of fetal hemoglobin. eLife 11, e65421 (2022).","journal-title":"eLife"},{"key":"1154_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32233-z","volume":"13","author":"MK Cromer","year":"2022","unstructured":"Cromer, M. K. et al. Ultra-deep sequencing validates safety of CRISPR\/Cas9 genome editing in human hematopoietic stem and progenitor cells. Nat. Commun. 13, 4724 (2022).","journal-title":"Nat. Commun."},{"key":"1154_CR14","doi-asserted-by":"publisher","first-page":"e0195558","DOI":"10.1371\/journal.pone.0195558","volume":"13","author":"T Del\u2019Guidice","year":"2018","unstructured":"Del\u2019Guidice, T. et al. Membrane permeabilizing amphiphilic peptide delivers recombinant transcription factor and CRISPR-Cas9\/Cpf1 ribonucleoproteins in hard-to-modify cells. PLoS ONE 13, e0195558 (2018).","journal-title":"PLoS ONE"},{"key":"1154_CR15","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/s41551-023-01032-2","volume":"7","author":"DV Foss","year":"2023","unstructured":"Foss, D. V. et al. Peptide-mediated delivery of CRISPR enzymes for the efficient editing of primary human lymphocytes. Nat. Biomed. Eng. 7, 647\u2013660 (2023).","journal-title":"Nat. Biomed. Eng."},{"key":"1154_CR16","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/s41587-023-01756-1","volume":"42","author":"Z Zhang","year":"2023","unstructured":"Zhang, Z. et al. Efficient engineering of human and mouse primary cells using peptide-assisted genome editing. Nat. Biotechnol. 42, 305\u2013315 (2023).","journal-title":"Nat. Biotechnol."},{"key":"1154_CR17","doi-asserted-by":"publisher","first-page":"6596","DOI":"10.1021\/jacs.8b01551","volume":"140","author":"R Rouet","year":"2018","unstructured":"Rouet, R. et al. Receptor-mediated delivery of CRISPR-Cas9 endonuclease for cell-type-specific gene editing. J. Am. Chem. Soc. 140, 6596\u20136603 (2018).","journal-title":"J. Am. Chem. Soc."},{"key":"1154_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12922-y","volume":"10","author":"S Krishnamurthy","year":"2019","unstructured":"Krishnamurthy, S. et al. Engineered amphiphilic peptides enable delivery of proteins and CRISPR-associated nucleases to airway epithelia. Nat. Commun. 10, 4906 (2019).","journal-title":"Nat. Commun."},{"key":"1154_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43904-w","volume":"14","author":"K Kulhankova","year":"2023","unstructured":"Kulhankova, K. et al. Shuttle peptide delivers base editor RNPs to rhesus monkey airway epithelial cells in vivo. Nat. Commun. 14, 8051 (2023).","journal-title":"Nat. Commun."},{"key":"1154_CR20","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.3390\/molecules24112079","volume":"24","author":"B Algayer","year":"2019","unstructured":"Algayer, B. et al. Novel pH selective, highly lytic peptides based on a chimeric influenza hemagglutinin peptide\/cell penetrating peptide motif. Molecules 24, 2079 (2019).","journal-title":"Molecules"},{"key":"1154_CR21","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nprot.2017.143","volume":"13","author":"RO Bak","year":"2018","unstructured":"Bak, R. O., Dever, D. P. & Porteus, M. H. CRISPR\/Cas9 genome editing in human hematopoietic stem cells. Nat. Protoc. 13, 358\u2013376 (2018).","journal-title":"Nat. Protoc."},{"key":"1154_CR22","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.ymthe.2019.05.014","volume":"27","author":"Z Romero","year":"2019","unstructured":"Romero, Z. et al. Editing the sickle cell disease mutation in human hematopoietic stem cells: comparison of endonucleases and homologous donor templates. Mol. Ther. 27, 1389\u20131406 (2019).","journal-title":"Mol. Ther."},{"key":"1154_CR23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41587-019-0325-6","volume":"38","author":"DN Nguyen","year":"2020","unstructured":"Nguyen, D. N. et al. Polymer-stabilized Cas9 nanoparticles and modified repair templates increase genome editing efficiency. Nat. Biotechnol. 38, 44\u201349 (2020).","journal-title":"Nat. Biotechnol."},{"key":"1154_CR24","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1182\/blood.2022019333","volume":"142","author":"V Vavassori","year":"2023","unstructured":"Vavassori, V. et al. Lipid nanoparticles allow efficient and harmless ex vivo gene editing of human hematopoietic cells. Blood 142, 812\u2013826 (2023).","journal-title":"Blood"},{"key":"1154_CR25","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1089\/crispr.2019.0074","volume":"3","author":"A Bothmer","year":"2020","unstructured":"Bothmer, A. et al. Detection and modulation of DNA translocations during multi-gene genome editing in T cells. CRISPR J. 3, 177\u2013187 (2020).","journal-title":"CRISPR J."},{"key":"1154_CR26","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1101\/gr.171322.113","volume":"24","author":"S Kim","year":"2014","unstructured":"Kim, S., Kim, D., Cho, S. W., Kim, J. & Kim, J.-S. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res. 24, 1012\u20131019 (2014).","journal-title":"Genome Res."},{"key":"1154_CR27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/d41587-021-00027-1","volume":"40","author":"C Sheridan","year":"2022","unstructured":"Sheridan, C. Off-the-shelf, gene-edited CAR-T cells forge ahead, despite safety scare. Nat. Biotechnol. 40, 5\u20138 (2022).","journal-title":"Nat. Biotechnol."},{"key":"1154_CR28","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","volume":"543","author":"J Eyquem","year":"2017","unstructured":"Eyquem, J. et al. Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection. Nature 543, 113\u2013117 (2017).","journal-title":"Nature"},{"key":"1154_CR29","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.3390\/ijms23031689","volume":"23","author":"A Rezalotfi","year":"2022","unstructured":"Rezalotfi, A., Fritz, L., F\u00f6rster, R. & Bo\u0161njak, B. Challenges of CRISPR-based gene editing in primary T cells. Int. J. Mol. Sci. 23, 1689 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1154_CR30","doi-asserted-by":"publisher","first-page":"10437","DOI":"10.1073\/pnas.1512503112","volume":"112","author":"K Schumann","year":"2015","unstructured":"Schumann, K. et al. Generation of knock-in primary human T cells using Cas9 ribonucleoproteins. Proc. Natl Acad. Sci. USA 112, 10437\u201310442 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1154_CR31","doi-asserted-by":"publisher","first-page":"E10907","DOI":"10.1073\/pnas.1809671115","volume":"115","author":"T DiTommaso","year":"2018","unstructured":"DiTommaso, T. et al. Cell engineering with microfluidic squeezing preserves functionality of primary immune cells in vivo. Proc. Natl Acad. Sci. USA 115, E10907\u2013E10914 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1154_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/hum.2023.29263.bfs","volume":"35","author":"A Philippidis","year":"2024","unstructured":"Philippidis, A. CASGEVY makes history as FDA approves first CRISPR\/Cas9 genome edited therapy. Hum. Gene Ther. 35, 1\u20134 (2024).","journal-title":"Hum. Gene Ther."},{"key":"1154_CR33","doi-asserted-by":"publisher","first-page":"21267","DOI":"10.1073\/pnas.2001367117","volume":"117","author":"L Schmiderer","year":"2020","unstructured":"Schmiderer, L. et al. Efficient and nontoxic biomolecule delivery to primary human hematopoietic stem cells using nanostraws. Proc. Natl Acad. Sci. USA 117, 21267\u201321273 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1154_CR34","doi-asserted-by":"publisher","first-page":"640082","DOI":"10.3389\/fimmu.2021.640082","volume":"12","author":"D Mart\u00ednez Bedoya","year":"2021","unstructured":"Mart\u00ednez Bedoya, D., Dutoit, V. & Migliorini, D. Allogeneic CAR T cells: an alternative to overcome challenges of CAR T cell therapy in glioblastoma. Front. Immunol. 12, 640082 (2021).","journal-title":"Front. Immunol."},{"key":"1154_CR35","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.3390\/cells11111843","volume":"11","author":"P Germino-Watnick","year":"2022","unstructured":"Germino-Watnick, P. et al. Hematopoietic stem cell gene-addition\/editing therapy in sickle cell disease. Cells 11, 1843 (2022).","journal-title":"Cells"},{"key":"1154_CR36","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.jcyt.2016.05.009","volume":"18","author":"U Mock","year":"2016","unstructured":"Mock, U. et al. Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy. Cytotherapy 18, 1002\u20131011 (2016).","journal-title":"Cytotherapy"},{"key":"1154_CR37","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jcyt.2021.11.004","volume":"24","author":"E Gotti","year":"2022","unstructured":"Gotti, E. et al. Optimization of therapeutic T cell expansion in G-Rex device and applicability to large-scale production for clinical use. Cytotherapy 24, 334\u2013343 (2022).","journal-title":"Cytotherapy"},{"key":"1154_CR38","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","volume":"385","author":"JD Gillmore","year":"2021","unstructured":"Gillmore, J. D. et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N. Engl. J. Med. 385, 493\u2013502 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1154_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17029-3","volume":"11","author":"T Wei","year":"2020","unstructured":"Wei, T., Cheng, Q., Min, Y.-L., Olson, E. N. & Siegwart, D. J. Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing. Nat. Commun. 11, 3232 (2020).","journal-title":"Nat. Commun."},{"key":"1154_CR40","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","volume":"15","author":"Q Cheng","year":"2020","unstructured":"Cheng, Q. et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat. Nanotechnol. 15, 313\u2013320 (2020).","journal-title":"Nat. Nanotechnol."},{"key":"1154_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01335-5","volume":"20","author":"L Miao","year":"2021","unstructured":"Miao, L., Zhang, Y. & Huang, L. mRNA vaccine for cancer immunotherapy. Mol. Cancer 20, 41 (2021).","journal-title":"Mol. Cancer"},{"key":"1154_CR42","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1154_CR43","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41596-022-00755-x","volume":"18","author":"X Wang","year":"2023","unstructured":"Wang, X. et al. Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery. Nat. Protoc. 18, 265\u2013291 (2023).","journal-title":"Nat. Protoc."},{"key":"1154_CR44","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jconrel.2022.02.017","volume":"344","author":"M Maeki","year":"2022","unstructured":"Maeki, M., Uno, S., Niwa, A., Okada, Y. & Tokeshi, M. Microfluidic technologies and devices for lipid nanoparticle-based RNA delivery. J. Control. Release 344, 80\u201396 (2022).","journal-title":"J. Control. Release"},{"key":"1154_CR45","doi-asserted-by":"publisher","first-page":"e4420","DOI":"10.21769\/BioProtoc.4420","volume":"12","author":"S-W Lin","year":"2022","unstructured":"Lin, S.-W., Nguyen, V. Q. & Lin, S. Preparation of Cas9 ribonucleoproteins for genome editing. Bio Protoc. 12, e4420 (2022).","journal-title":"Bio Protoc."},{"key":"1154_CR46","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1038\/nprot.2007.454","volume":"2","author":"I Coin","year":"2007","unstructured":"Coin, I., Beyermann, M. & Bienert, M. Solid-phase peptide synthesis: from standard procedures to the synthesis of difficult sequences. Nat. Protoc. 2, 3247\u20133256 (2007).","journal-title":"Nat. Protoc."},{"key":"1154_CR47","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41587-019-0032-3","volume":"37","author":"K Clement","year":"2019","unstructured":"Clement, K. et al. CRISPResso2 provides accurate and rapid genome editing sequence analysis. Nat. Biotechnol. 37, 224\u2013226 (2019).","journal-title":"Nat. Biotechnol."},{"key":"1154_CR48","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1016\/j.cell.2023.08.041","volume":"186","author":"CA Tsuchida","year":"2023","unstructured":"Tsuchida, C. A. et al. Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells. Cell 186, 4567\u20134582.e20 (2023).","journal-title":"Cell"},{"key":"1154_CR49","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.stem.2024.11.001","volume":"32","author":"J Zeng","year":"2024","unstructured":"Zeng, J. et al. Gene editing without ex vivo culture evades genotoxicity in human hematopoietic stem cells. Cell Stem Cell 32, 191\u2013208.e11 (2024).","journal-title":"Cell Stem Cell"},{"key":"1154_CR50","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1089\/hum.2023.29234.bfs","volume":"34","author":"A Philippidis","year":"2023","unstructured":"Philippidis, A. Graphite bio pauses lead gene editing program in sickle cell disease. Hum. Gene Ther. 34, 90\u201393 (2023).","journal-title":"Hum. Gene Ther."},{"key":"1154_CR51","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281\u20132308 (2013).","journal-title":"Nat. Protoc."},{"key":"1154_CR52","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/nbt.3290","volume":"33","author":"A Hendel","year":"2015","unstructured":"Hendel, A. et al. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat. Biotechnol. 33, 985\u2013989 (2015).","journal-title":"Nat. Biotechnol."},{"key":"1154_CR53","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1089\/crispr.2021.0134","volume":"5","author":"T Rathbone","year":"2022","unstructured":"Rathbone, T. et al. Electroporation-mediated delivery of Cas9 ribonucleoproteins results in high levels of gene editing in primary hepatocytes. CRISPR J. 5, 397\u2013409 (2022).","journal-title":"CRISPR J."},{"key":"1154_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05073-z","volume":"9","author":"A Mir","year":"2018","unstructured":"Mir, A. et al. Heavily and fully modified RNAs guide efficient SpyCas9-mediated genome editing. Nat. Commun. 9, 2641 (2018).","journal-title":"Nat. Commun."},{"key":"1154_CR55","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1101\/gr.231936.117","volume":"28","author":"S Kim","year":"2018","unstructured":"Kim, S. et al. CRISPR RNAs trigger innate immune responses in human cells. Genome Res. 28, 367\u2013373 (2018).","journal-title":"Genome Res."},{"key":"1154_CR56","doi-asserted-by":"publisher","first-page":"e2148","DOI":"10.21769\/BioProtoc.2148","volume":"7","author":"T Zhang","year":"2017","unstructured":"Zhang, T., Gao, Y., Wang, R. & Zhao, Y. Production of guide RNAs in vitro and in vivo for CRISPR using ribozymes and RNA polymerase II promoters. Bio Protoc. 7, e2148 (2017).","journal-title":"Bio Protoc."},{"key":"1154_CR57","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/s41591-019-0401-y","volume":"25","author":"Y Wu","year":"2019","unstructured":"Wu, Y. et al. Highly efficient therapeutic gene editing of human hematopoietic stem cells. Nat. Med. 25, 776\u2013783 (2019).","journal-title":"Nat. Med."},{"key":"1154_CR58","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.1182\/bloodadvances.2019000820","volume":"3","author":"J-Y M\u00e9tais","year":"2019","unstructured":"M\u00e9tais, J.-Y. et al. Genome editing of HBG1 and HBG2 to induce fetal hemoglobin. Blood Adv. 3, 3379\u20133392 (2019).","journal-title":"Blood Adv."},{"key":"1154_CR59","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1016\/j.ymthe.2023.06.019","volume":"31","author":"EC Stahl","year":"2023","unstructured":"Stahl, E. C. et al. Genome editing in the mouse brain with minimally immunogenic Cas9 RNPs. Mol. Ther. 31, 2422\u20132438 (2023).","journal-title":"Mol. Ther."},{"key":"1154_CR60","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nbt.3806","volume":"35","author":"BT Staahl","year":"2017","unstructured":"Staahl, B. T. et al. Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes. Nat. Biotechnol. 35, 431\u2013434 (2017).","journal-title":"Nat. Biotechnol."},{"key":"1154_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24017-8","volume":"12","author":"L Zhang","year":"2021","unstructured":"Zhang, L. et al. AsCas12a ultra nuclease facilitates the rapid generation of therapeutic cell medicines. Nat. Commun. 12, 3908 (2021).","journal-title":"Nat. Commun."},{"key":"1154_CR62","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1089\/genbio.2022.0003","volume":"1","author":"K Luk","year":"2022","unstructured":"Luk, K. et al. Optimization of nuclear localization signal composition improves CRISPR-Cas12a editing rates in human primary cells. GEN Biotechnol. 1, 271\u2013284 (2022).","journal-title":"GEN Biotechnol."},{"key":"1154_CR63","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41587-018-0011-0","volume":"37","author":"BP Kleinstiver","year":"2019","unstructured":"Kleinstiver, B. P. et al. Engineered CRISPR-Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing. Nat. Biotechnol. 37, 276\u2013282 (2019).","journal-title":"Nat. Biotechnol."},{"key":"1154_CR64","volume":"2022","author":"D Fang","year":"2022","unstructured":"Fang, D., Wang, R., Yu, X. & Tian, Y. Construction of cyclic cell-penetrating peptides for enhanced penetration of biological barriers. J. Vis. Exp. 2022, e64293 (2022).","journal-title":"J. Vis. Exp."},{"key":"1154_CR65","volume":"2019","author":"S Fripont","year":"2019","unstructured":"Fripont, S., Marneffe, C., Marino, M., Rincon, M. Y. & Holt, M. G. Production, purification, and quality control for adeno-associated virus-based vectors. J. Vis. Exp. 2019, e58960 (2019).","journal-title":"J. Vis. Exp."},{"key":"1154_CR66","volume":"2011","author":"C McClure","year":"2011","unstructured":"McClure, C., Cole, K. L. H., Wulff, P., Klugmann, M. & Murray, A. J. Production and titering of recombinant adeno-associated viral vectors. J. Vis. Exp. 2011, e3348 (2011).","journal-title":"J. Vis. Exp."},{"key":"1154_CR67","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1038\/nprot.2006.207","volume":"1","author":"JC Grieger","year":"2006","unstructured":"Grieger, J. C., Choi, V. W. & Samulski, R. J. Production and characterization of adeno-associated viral vectors. Nat. Protoc. 1, 1412\u20131428 (2006).","journal-title":"Nat. Protoc."},{"key":"1154_CR68","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s41587-022-01418-8","volume":"41","author":"BR Shy","year":"2023","unstructured":"Shy, B. R. et al. High-yield genome engineering in primary cells using a hybrid ssDNA repair template and small-molecule cocktails. Nat. Biotechnol. 41, 521\u2013531 (2023).","journal-title":"Nat. Biotechnol."},{"key":"1154_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-41121-4","volume":"9","author":"S Okamoto","year":"2019","unstructured":"Okamoto, S., Amaishi, Y., Maki, I., Enoki, T. & Mineno, J. Highly efficient genome editing for single-base substitutions using optimized ssODNs with Cas9-RNPs. Sci. Rep. 9, 4811 (2019).","journal-title":"Sci. Rep."},{"key":"1154_CR70","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1089\/crispr.2021.0113","volume":"5","author":"D Conant","year":"2022","unstructured":"Conant, D. et al. Inference of CRISPR edits from Sanger trace Data. CRISPR J. 5, 123\u2013130 (2022).","journal-title":"CRISPR J."},{"key":"1154_CR71","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1093\/nar\/gku936","volume":"42","author":"EK Brinkman","year":"2014","unstructured":"Brinkman, E. K., Chen, T., Amendola, M. & van Steensel, B. Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res. 42, e168 (2014).","journal-title":"Nucleic Acids Res."},{"key":"1154_CR72","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1093\/nar\/gky164","volume":"46","author":"EK Brinkman","year":"2018","unstructured":"Brinkman, E. K. et al. Easy quantification of template-directed CRISPR\/Cas9 editing. Nucleic Acids Res. 46, e58 (2018).","journal-title":"Nucleic Acids Res."},{"key":"1154_CR73","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1089\/crispr.2018.0014","volume":"1","author":"MG Kluesner","year":"2018","unstructured":"Kluesner, M. G. et al. EditR: a method to quantify base editing from Sanger sequencing. CRISPR J. 1, 239\u2013250 (2018).","journal-title":"CRISPR J."},{"key":"1154_CR74","doi-asserted-by":"publisher","first-page":"e20211530","DOI":"10.1084\/jem.20211530","volume":"219","author":"SA Oh","year":"2022","unstructured":"Oh, S. A. et al. High-efficiency nonviral CRISPR\/Cas9-mediated gene editing of human T cells using plasmid donor DNA. J. Exp. Med. 219, e20211530 (2022).","journal-title":"J. Exp. Med."},{"key":"1154_CR75","doi-asserted-by":"publisher","first-page":"586168","DOI":"10.3389\/fimmu.2020.586168","volume":"11","author":"K Hoerster","year":"2020","unstructured":"Hoerster, K. et al. HLA class I knockout converts allogeneic primary NK cells into suitable effectors for \u2018Off-the-Shelf\u2019 immunotherapy. Front. Immunol. 11, 586168 (2020).","journal-title":"Front. Immunol."},{"key":"1154_CR76","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/bioinformatics\/btm091","volume":"23","author":"T Koressaar","year":"2007","unstructured":"Koressaar, T. & Remm, M. Enhancements and modifications of primer design program Primer3. Bioinformatics 23, 1289\u20131291 (2007).","journal-title":"Bioinformatics"},{"key":"1154_CR77","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1093\/nar\/gks596","volume":"40","author":"A Untergasser","year":"2012","unstructured":"Untergasser, A. et al. Primer3\u2014new capabilities and interfaces. Nucleic Acids Res. 40, e115 (2012).","journal-title":"Nucleic Acids Res."},{"key":"1154_CR78","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1093\/bioinformatics\/bty036","volume":"34","author":"T K\u00f5ressaar","year":"2018","unstructured":"K\u00f5ressaar, T. et al. Primer3_masker: integrating masking of template sequence with primer design software. Bioinformatics 34, 1937\u20131938 (2018).","journal-title":"Bioinformatics"},{"key":"1154_CR79","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-13-134","volume":"13","author":"J Ye","year":"2012","unstructured":"Ye, J. et al. Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction. BMC Bioinformatics 13, 134 (2012).","journal-title":"BMC Bioinformatics"}],"container-title":["Nature Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41596-025-01154-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41596-025-01154-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41596-025-01154-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T14:03:16Z","timestamp":1759759396000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41596-025-01154-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":79,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1154"],"URL":"https:\/\/doi.org\/10.1038\/s41596-025-01154-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.07.14.603391","asserted-by":"object"}]},"ISSN":["1754-2189","1750-2799"],"issn-type":[{"value":"1754-2189","type":"print"},{"value":"1750-2799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,3]]},"assertion":[{"value":"22 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.N.N., S.U.S. and R.C.W. are named inventors on a patent application related to this work. J.E. is a compensated co-founder at Mnemo Therapeutics, a compensated scientific advisor to Cytovia Therapeutics, owns stocks in Mnemo Therapeutics and Cytovia Therapeutics, is a compensated member of the scientific advisory board at Treefrog Therapeutics and has received a consulting fee from Casdin Capital. The J.E. laboratory has received research support from Cytovia Therapeutics, Mnemo Therapeutics and Takeda. J.E. is a holder of patents pertaining to but not resulting from this work. R.C.W. is a co-founder of Editpep, Inc. D.N.N. is a consultant for and owns stock in Navan Technologies.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}